APPLICATION OF CD45 AS BIOMARKER IN SCREENING EFFECTIVENESS AND PRECISION OF CD26 ANTIBODY OR DERIVATIVE THEREOF IN TREATING TUMORS

Provided is an application of CD45 as a biomarker in screening the effectiveness of a CD26 antibody or a derivative thereof in treating tumors in a test subject. Specifically, when CD45 is not expressed or has low expression, determining that the treatment of the test subject who has received a CD26 antibody or a derivative thereof is effective or has a high probability of being effective; and when CD45 expression is high or relatively high, determining that the treatment of the test subject who has received a CD26 antibody or a derivative thereof is ineffective or has a high probability of being ineffective. By filtering-out a biomarker capable of effectively screening the tumor treatment effectiveness of a CD26 antibody or derivative thereof, it is possible to greatly improve the precision and effectiveness of tumor treatment by the CD26 antibody or derivative thereof, thus improving the clinical benefit to the patient; it has been found that CD26 acts as a new mechanism for treatment effectiveness and prec